|
ChemRar High-Tech Center has entered into an Initial Non-Binding Agreement on Collaboration with Janssen Pharmaceutica NV. The document outlines that the parties intend to work to identify and explore joint research projects with the intention to contribute to the innovative development of the Russian pharmaceutical industry.
NPO ChemRar High-Tech Center and Janssen Pharmaceutica NV plan to cooperate with Russian leading R&D centers and academic institutions to identify and select for funding initiatives in the biotechnology and medical device sectors, which may be transformed into startup companies with promising commercial prospects. ChemRar High-Tech and Janssen Pharmaceutica NV Center have outlined their desire to explore providing venture funding to Russian start-ups companies. These strart-ups may seek support of Skolkovo foundation and other interested parties. The main task is to stimulate the innovation process in R&D while preparing Russian companies to thrive in a highly competitive global biotechnology and medical device market.
As it was communicated in a joint press statement with Skolkovo Foundation distributed on Friday at the International Economic Forum in Saint-Petersburg by Naira Adamian, Head of Representation of Janssen Pharmaceutica NV in Russia, this proposed involvement will seek to contribute to the modernization of the Russian biotechnology and medical device industries and the making of innovative medicines and other health care product offerings more accessible for Russian patients.
The signed document also identifies other areas of potential collaboration: namely a collaboration to train a new Good Laboratory Practice (“GLP”), accredited toxicology facility, a discovery collaboration and a co-development of Janssen assets.
According to Andrey Ivashchenko, Chairman of the Board of Directors, ChemRar High-Tech Center: “The key outcome of the potential collaboration between our companies will be broader accessibility of innovative medicines, developed under the cooperation of Russian and foreign scientists, for Russian patients. This is in line with goals and objectives of the State strategy on modernization of pharmaceutical and healthcare industry of the Russian Federation till 2020. Despite of the fact that the creation and commercialization of any innovation drug is a complicated and long-term process, this task seems to be quite feasible, taking into account that the specialists from ChemRar organizations have twenty-year international experience and the most modern research methods. I would like to emphasize that we are sincerely delighted that our close partnership with Johnson&Johnson on contract research becomes extended and acquires new forms including establishment of joint venture capital with risk and market sharing models. Janssen is a worldwide company with impeccable international reputation and rich experience. Russia critically needs exactly this kind of investors who come with so-called "smart money" and help to complete establishment of innovation infrastructure in Russian Federation in accordance with international standards, therethrough ensuring the future competitiveness of joint developments at the global level. "
Specific details on the activities described above will be communicated as far as projects will be developed.
About ChemRar High-Tech center
Non-commercial partnership ChemRar High Technology Center is a unique complex of research, production and investment facilities operating in the fields of development and commercialization of innovative medicines for treatment of cardiovascular diseases, endocrinology, infectious diseases, oncology, and CNS diseases both in Russia and abroad.
ChemRar Ventures is a Russian venture company managing the diversified portfolio of investments into innovative biotechnological and biopharmaceutical companies. www.chemrar.ru
Contacts for media:
ChemRar HTC
Irina Tyrnova
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
+7 (985) 776 12 40
|
What's New 
